Multiple myeloma is a malignant disorder of clonal plasma cells with a median survival of approximately 3 years with standard therapy. 1, 2 The median survival of patients who are less than 65 years old and respond to initial chemotherapy is 5 years. 3 Combination chemotherapy in standard doses has not been shown to prolong survival over treatment with oral melphalan and prednisone. [4] [5] [6] High-dose therapy with autologous hematopoietic stem cell transplantation has been shown to increase overall and disease-free survival. [7] [8] [9] Early transplant was associated with longer progression-free survival. 10, 11 Unfortunately, approximately 50% of patients relapse within 5 years of autologous transplant. [12] [13] [14] A subset of patients without chromosome 13 abnormalities and low b-2 microglobulin were reported to have a 52% continuous complete remission rate after tandem autologous transplant. 15 Recently, a randomized study has shown a survival advantage to tandem (double) autologous stem cell transplant compared to single autologous stem cell transplant. 16 The projected overall survival (OS) at seven years was 42% for the recipients of the double autologous stem cell transplant approach and 21% for the recipients of the single transplant. Even with these aggressive autologous approaches, there is no plateau in the survival curve. Thus, most patients will relapse and die of their disease.
Allogeneic stem cell transplant using matched related donors has been studied as a way of reducing the relapse rate and improving survival, due to tumor-free grafts and a graftversus-myeloma effect. 17, 18 Long-term, disease-free survival rates of 20-55% have been observed. 19, 20 A graft-versusmyeloma effect has been demonstrated; patients with graftversus-host disease (GVHD) have a lower risk of relapse. 17 Adverse risk factors for outcome include longer time from diagnosis to transplant, a high pretransplant b-2 microglobulin level, chemotherapy resistance, extensive prior treatment, and Durie Salmon Stage III. 21 Reduced-intensity conditioning regimens have been used more recently with reported event-free survival rates of 20-35%. 22, 23 However, only 25-30% of patients have a matched sibling donor. 24 The National Marrow Donor Program (NMDP) was established to provide a source of volunteer bone marrow donors for patients who do not have a matched family donor. 25 The NMDP has over 4 million volunteer bone marrow donors and has facilitated over 10 000 transplants. Most of these transplants have been for leukemia, and less than 1% has been for myeloma. 25 Longterm disease control can be achieved in patients with a variety of hematologic malignancies, with the best results reported for young patients in first chronic phase CML receiving molecularly matched bone marrow; single center studies have reported up to a 70% probability of diseasefree survival. 26 In this study, we examined the results of unrelated bone marrow transplants for multiple myeloma to determine outcomes and prognostic factors for early death, GVHD, disease-free survival, and OS.
Patients and methods

Patients
A total of 71 consecutive patients received an unrelated hematopoietic stem cell transplant facilitated by the NMDP between July 1989 and February 2000 for multiple myeloma. Transplant centers reported recipient outcome data to the NMDP Coordinating Center on standardized NMDP forms submitted at the time of transplantation (baseline), and at 100 days, 6 months, and annually thereafter. In addition, transplant centers completed a supplemental data collection form specific to multiple myeloma. All patients included in the analysis signed an informed consent form for data submission to the NMDP that was approved by the Institutional Review Board at their transplant center. The one patient who did not consent to data submission was excluded from the analysis. Bone marrow was procured via NMDP policy at an NMDP member collection center. All patients received a myeloablative conditioning regimen.
Statistical analysis
End points analyzed in this study were OS, progression-free survival, treatment-related mortality (TRM), relapse, neutrophil engraftment, acute GVHD (aGVHD), and chronic GVHD (cGVHD). Prognostic factors were examined for each end point using univariate analyses. The KaplanMeier and log-rank methods were used in the univariate analysis of OS and continuous complete remission. 27, 28 Relapse, engraftment, acute and chronic GVHD were calculated using cumulative incidence, with death treated as a competing risk. Treatment-related (nonrelapse) mortality was also calculated using cumulative incidence, with relapse treated as a competing risk. 29 Engraftment was defined as the first of 3 days demonstrating an absolute neutrophil count 4500 ml. Complete remission was defined as the absence of original monoclonal paraprotein in urine and serum by routine electrophoresis and by immunofixation, o5% plasma cells in marrow aspirate, no increase in size or number of lytic bony lesions, and disappearance of soft tissue plasmacytomas. Relapse was defined as reappearance of serum or urinary paraprotein, 45% plasma cells in marrow aspirate, development of new lytic bone lesions, or development of hypercalcemia not attributable to any other cause. 30 Progressive disease, for patients not in complete remission, was defined as one or more of the following: (1) 425% increase in serum monoclonal protein, urinary light chain excretion, or plasma cells in bone marrow, (2) increase in size of or development of a new bony lesion, (3) development of hypercalcemia not attributable to any other cause. 30 The proportional hazards regression model was used for multivariate analyses of survival, relapse, Grades II-IV GVHD, and engraftment. 31 The multivariate models included risk factor where the Wald w 2 P-value was less than 0.05. Transplant center effects were included in each model. Other risk factors considered were patient age and gender, donor age and gender, CMV status, HLA matching, Karnofsky score prior to conditioning, Salmon-Durie stage prior to conditioning, use of total body irradiation, previous autologous transplant, interval from diagnosis to BMT, and T-cell depletion of marrow.
Results
Patients
In total, 70 patients with multiple myeloma received unrelated bone marrow transplants facilitated by the NMDP between July 1989 and February 2000. Table 1 outlines the patient and donor characteristics. In all, 59% of the patients and 60% of the donors were male. The median patient age was 44 years (range 22-60 years). The median time from diagnosis to unrelated transplant was 17 months (range 5-215 months). In all, 31% of these patients had received a prior autologous transplant; 64% of patients and donors were matched at Class I and a molecular match at DRB 1. A potential match at DRB1 was scored if low or intermediate resolution typing did not resolve the allele. The majority of patients (64%) received a TBI-based conditioning regimen. In total, 39% of patients received a T-cell-depleted graft; 40% had received one or two treatment regimens pretransplant; 55% of patients were in a complete or partial response at the time of conditioning.
Survival
With a median follow-up of 71 months (range 41-98 months), five patients (7%) were alive at the time of this analysis. The Kaplan-Meier estimate for overall survival at 2 years was 27710%, and at 5 years, 977% (Figure 1 ). The 5-year Kaplan-Meier estimate for survival from a male donor was 13711% and from a female donor 477% (P ¼ 0.05). The actuarial Kaplan-Meier estimate for progression-free survival at 2 years was 19%, and 7% at 5 years. (Figure 2 ) The year of transplant did not affect survival. Patients transplanted between 1989 and 1996 had 9% survival at 5 years; patients transplanted in 1997-2000 had 10% survival at 5 years.
Prognostic indicators for OS
A univariate analysis of variables that often affect survival after transplantation is described in Table 2 . HLA match, donor age, recipient age, patient gender, CMV status, performance status, conditioning regimen, T-cell depletion, time to transplant, and prior transplant had no significant effect on OS. Patients with a lower Salmon-Durie stage at conditioning had improved survival -41 vs 19%, P ¼ 0.03. b-2 microglobulin, creatinine, calcium level, immunoglobulin subtype, and hemoglobin were also studied and had no effect on survival (data not shown). In multivariate analysis, only male donors (regardless of recipient gender) were associated with better survival (P ¼ 0.03).
Engraftment
In all, 63 patients (91%) engrafted. The degree of mismatch did not affect time to engraftment.
Remission and progression-free survival
The best response to transplant was a complete response in 32% of patients, and a partial response in 18% of patients. The 3-year cumulative incidence estimate for relapse was 34710%. The 6-year relapse rate was 37%. An additional three patients relapsed between 3 and 6 years post transplant. The 100-day TRM was 42711%. The most common cause of TRM by day þ 100 was infection, followed by end organ toxicity (Table 3) . A total of 16 patients died of infection; five of these deaths were related to fungal infection, three to bacterial infection, one to CMV disease, and one to pneumocystis pneumonia. Six of Unrelated BMT for myeloma KK Ballen et al these infectious deaths were not further described. Six deaths were related to end organ toxicity, involving the lungs, kidney, heart, or central nervous system.
GVHD
In all, 40 patients developed Grades II-IV acute GVHD post transplant, with a 100-day cumulative incidence estimate of 47711%. The incidence of Grade III-IV acute GVHD was 34711%. Performance status was not a risk factor for GVHD. Female donor was a borderline risk factor for GVHD in multivariate analysis (P ¼ 0.05). T-cell depletion was not significant for GVHD in univariate analysis (P ¼ 0.87), but was significant in multivariate analysis (P ¼ 0.01), with higher GVHD seen in those patients receiving pharmacologic prophylaxis rather than T-cell depletion. This difference was due to an interaction between donor gender and GVHD; the risk of acute GVHD was lower in T-celldepleted transplants only in combination with a male donor. In all, 21% patients died of infection; 13 of these patients had concomitant Grade II-IV GVHD. cGVHD was not associated with a decrease risk of relapse. The relapse rate at 3 years was 31% for patients with cGVHD and 34% for patients without cGVHD (P ¼ 0.83).
Second BMT
In all, 31% of patients had received a prior autologous transplant. Patients with a prior autologous transplant had a poor outcome. The 3-year survival of patients who had received a prior autologous transplant was 5%; the 3-year survival for those patients who had not received a prior autologous transplant was 25%. However, this difference was not statistically significant (P ¼ 0.10). TRM at 100 days was 45718% for those patients receiving an allogeneic second transplant. The major cause of death in all patients, those who did and did not have prior autologous transplants, was infection. The risk of relapse was similar in both groups. The median time interval from autologous to unrelated transplant was 20 months (range 2-41 months).
Discussion
We demonstrated that survival after myeloablative unrelated bone marrow transplant for multiple myeloma was poor, with a 5-year OS of only 9%. In total, 50% of patients achieved a complete or partial remission; the relapse rate of 34% was lower than reported after autologous transplant. 7, 8 However, the 100-day TRM Infection  16  50  Toxicity  6  19  GVHD  5  16  Other  2  6  Hemorrhage  2  6  Recurrent disease  1  3 was high, at 42%, mostly due to infection. This TRM for transplants for multiple myeloma was higher than that reported for selected patients with leukemia. 26, 32 Although the TRM following unrelated donor transplant was quite high, this was similar to mortality rates reported after matched ablative sibling transplants for multiple myeloma. The Seattle group reported a 100-day nonrelapse mortality of 44%. 21 Disease-free survival was 20% at 4.5 years in this study. The European Group for Blood and Marrow Transplantation reported a 41% TRM after matched sibling transplants for multiple myeloma. 33 More recent studies using related donors and an ablative conditioning regimen have reported 100-day TRM rates of 16%. 18, 34 A total of 47% of patients in this study developed acute Grades II-IV GVHD, although 39% of patients received a T-cell-depleted graft. The risk of GVHD reported after sibling transplants for multiple myeloma has ranged from 19 to 63%. [18] [19] [20] [21] A number of investigators have reported a graft-versus-myeloma effect, suggesting an important effect of the immune system that could be harnessed with unrelated transplant. 18, 35 Since the risk of GVHD is often higher in unrelated than allogeneic transplant, this benefit of graft-versus-myeloma effect may be stronger for unrelated recipients. However, the presence of GVHD did not correlate with a lower relapse rate, perhaps due to the small sample size and the high TRM in this study. cGVHD, which has been shown to correlate with a decreased risk of relapse in some studies, also did not correlate with a decreased risk of relapse. 36 Most of the patients in this study had received more than two chemotherapy regimens prior to transplant. A total of 43% of patients had a performance status of less than 90%, indicating a high-risk group of patients. A total of 31% of patients had received a prior autologous transplant. Patients who had received a prior autologous transplant did very poorly, with a 3-year actuarial survival of 5%, although this was not statistically significant compared to the patients who had not received a prior autologous transplant. In multivariate analysis, only male donor was associated with improved survival. Prognostic factors such as cytogenetics and b-2 microglobulin were not available for all patients. Certain patients with multiple myeloma may fare worse after autologous transplant, such as those patients with a high b-2 microglobulin level, duration of therapy 412 months, and chromosome 13 abnormalities. These may be the patients more likely to come to unrelated transplant. 13, 37, 38 Traditionally, conditioning regimens for unrelated transplant have consisted of myeloablative chemotherapy or chemoradiotherapy. 39 Work by Giralt et al, 40 Slavin et al, 41 and others has shown that durable engraftment and disease-free survival can be obtained by using nonablative chemotherapy in the allogeneic setting. 42 These conditioning regimens were well tolerated even in older, heavily pretreated patients, and therefore would be appropriate for patients with multiple myeloma. The Arkansas group reported on 31 multiple myeloma patients, including six patients who received a graft from an unrelated donor, who received a nonmyeloablative melphalan-based regimen. 43 In all, 89% of patients were full donor chimeras, and the TRM was 10% at 100 days, lower than that reported after myeloablative allogeneic transplants. 21 The OS at 1 year was 71%; the TRM at 1 year was 29%. Multiple myeloma patients (22) at MD Anderson, including nine patients who received an unrelated graft, were conditioned with melphalan and fludarabine. 44 All patients achieved donor engraftment, and the 100-day TRM was 19%. The OS at 2 years was 30%.
Recently, the nonmyeloablative transplant approach has been studied in multiple myeloma patients receiving unrelated transplants. Kroger et al 45 analyzed 21 patients conditioned with melphalan, fludarabine, and antithymocyte globulin. The 100-day TRM was 10%. Follow-up was only 13 months, and the 2-year projected progression-free survival was 53%, superior to the 17% 2-year progression-free survival observed in our study with longer follow-up. Shaw et al 46 treated 45 multiple myeloma patients with unrelated transplant; 17 received a myeloablative conditioning regimen and 28% received a reduced-intensity or nonmyeloablative regimen. The 100-day TRM was 18% in the reduced-intensity group and 53% in the myeloablative group. With a median follow-up of 16 months, the OS was 54% in the reduced-intensity group and 18% in the myeloablative group.
Another approach is to perform a nonablative approach after autologous transplant. The Seattle group reported on 54 patients undergoing this sequence of therapy. 47 The complete response rate was 57%, TRM 4% (17% at 1 year), and the 18-month OS was 78%. Kroger et al 48 has tried a similar approach in 17 patients, including eight patients with unrelated donors. The TRM was 11%, and 12 patients are alive without progression with a median follow-up of 13 months.
Our series represents the largest report of patients to receive unrelated transplants for multiple myeloma, and with the longest follow-up. The study is a retrospective registry analysis, and limited by selection bias and incomplete data reporting for pretransplant parameters such as cytogenetics. The median follow-up was 71 months. All patients received myeloablative transplants, as all were transplanted before 2001. Long-term outcome was poor, and this approach cannot be recommended. Some of the studies cited above included both related and unrelated recipients, but the number of patients receiving an unrelated transplant was small. 43, 44 We postulate that survival after unrelated transplant for multiple myeloma would be improved in younger patients earlier in the course of their disease, with higher performance status, and with a nonmyeloablative preparative regimen. Extending this nonablative approach to unrelated patients, early in the course of disease, may reduce the toxicity of transplant and improve outcomes, which may eliminate the need for conventional unrelated donor transplant. The NMDP will soon be analyzing the outcome data for multiple myeloma patients receiving a nonmyeloablative regimen, after a longer period of follow-up.
